Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;22(6):545-553.
doi: 10.5223/pghn.2019.22.6.545. Epub 2019 Nov 7.

Lactobacillus reuteri DSM 17938 Improves Feeding Intolerance in Preterm Infants

Risma K Kaban  1 , Wardhana  1 , Badriul Hegar  1 , Rinawati Rohsiswatmo  1 , Setyo Handryastuti  1 , Novie Amelia  1 , Dina Muktiarti  1 , Flavia Indrio  2 , Yvan Vandenplas  3
Affiliations

Lactobacillus reuteri DSM 17938 Improves Feeding Intolerance in Preterm Infants

Risma K Kaban et al. Pediatr Gastroenterol Hepatol Nutr. 2019 Nov.

Abstract

Purpose: Feeding tolerance is extremely important in preterm infants. This study aimed to evaluate whether preterm infants receiving Lactobacillus reuteri DSM 17938 would develop fewer symptoms of feeding intolerance. Secondary outcomes were duration of parenteral nutrition, time to reach full feeding, length of hospital stay, sepsis, necrotizing enterocolitis (NEC), diarrhea, and mortality.

Methods: This double-blind randomized controlled trial of L. reuteri DSM 17938 versus placebo included 94 neonates with a gestational age of 28-34 weeks and birth weight of 1,000-1,800 g.

Results: Feeding intolerance (vomiting and/or distension) was less common in the probiotic group than in the placebo group (8.5% vs. 25.5%; relative risk, 0.33; 95% confidence interval, 0.12-0.96; p=0.03). No significant intergroup differences were found in proven sepsis, time to reach full feeding, length of hospital stay, or diarrhea. The prevalence of NEC (stages 2 and 3) was 6.4% in the placebo group vs. 0% in the probiotic group (relative risk, 1.07; 95% confidence interval, 0.99-1.15; p=0.24). Mortality rates were 2.1% in the probiotic group and 8.5% in the placebo group, p=0.36).

Conclusion: The administration of L. reuteri DSM 17938 to preterm infants was safe and significantly reduced feeding intolerance. No significant differences were found in any other secondary outcomes.

Keywords: Feeding intolerance; Lactobacillus reuteri; Preterm.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: FI has participated as a clinical investigator and/or advisory board member and/or consultant and/or speaker for Abbott, Biogaia, Danone, and Nestle Nutrition Institute. YV has participated as a clinical investigator and/or advisory board member and/or consultant and/or speaker for Abbott Nutrition, Biocodex, Danone, Nestle Health Science, Nestle Nutrition Institute, Nutricia, Mead Johnson, Phacobel, and United Pharmaceuticals.

References

    1. de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol. 2008;111:1–66. - PubMed
    1. Sinkiewicz G, Ljunggren L. Occurrence of Lactobacillus reuteri in human breast milk. Microb Ecol Health Dis. 2008;20:112–116.
    1. Thomas DW, Greer FR American Academy of Pediatrics Committee on Nutrition; American Academy of Pediatrics Section on Gastroenterology, Hepatology, and Nutrition. Probiotics and prebiotics in pediatrics. Pediatrics. 2010;126:1217–1231. - PubMed
    1. Pietzak M. Bacterial colonization of the neonatal gut. J Pediatr Gastroenterol Nutr. 2004;38:389–391. - PubMed
    1. Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr Issues Intest Microbiol. 2001;2:43–53. - PubMed